AllanHu your clinical reasoning is flawed.
Also, bare in mind that the primary efficacy end point wasn't met....as they weren't actually able to test for it in the majority of the trial population (due to ''the high rate of pump thrombosis reducing the number of evaluable weans'').
However, in the portion of the trial population (44%) that they were able to test for temporary weans from a LVAD, a ''significant beneficial effect'' was observed ''(p-value = 0.02)''.
(Nailsnglue also touches on this in his previous recent posts)
This in turn is encouraging for a possible positive outcome for the larger heart failure trial that is about 85% enrolled.
Let’s not get excited about stem cells and GI bleeding, page-2
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78561 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 114667 | 4 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |